MVT-602
Chemical compound
From Wikipedia, the free encyclopedia
MVT-602 (other developmental code names RVT-602, TAK-448) is a kisspeptin receptor agonist which is under development for the treatment of female infertility and hypogonadism.[1][2] It has been found to increase luteinizing hormone levels in premenopausal women.[2] As of March 2021, MVT-602 is in phase 2 clinical trials for the treatment of female infertility and hypogonadism.[1] It was also under development for the treatment of prostate cancer, but development for this indication was discontinued.[1]
| Clinical data | |
|---|---|
| Other names | RVT-602; TAK-448 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C58H80N16O14 |
| Molar mass | 1225.376 g·mol−1 |
| 3D model (JSmol) | |
| |
| |